Acrivon Buys Phase 2-Ready Oral JAK1 Inhibitor, Expands Into Immunology
ACRV sits 24% above its 52-week low of $1.27.
Summary
Acrivon acquired ACR-525, a Phase 2-ready oral JAK1 inhibitor, plus a preclinical PKCθ program from Aqilion AB for undisclosed cash with no future royalties or milestones. The deal adds a clinical-stage immunology and inflammation pillar alongside its oncology pipeline and comes with a concurrent termination of Aqilion's prior royalty and milestone obligations to LEO Pharma on ACR-525. Acrivon's AP3 profiling against six approved JAK inhibitors and dupilumab characterized ACR-525 as highly selective with minimal off-target effects, and the company is targeting eosinophilic esophagitis as the first indication using a formulation built for patients with difficulty swallowing. The terms are undisclosed, so the cash outlay and dilution risk are unknown, but the no-royalty, no-milestone structure keeps future obligations off the books. Acrivon had $90.0M in cash as of Q2 expected to fund operations into Q4 2027, so the purchase price matters for how much runway is consumed. A KOL webcast on November 10, 2026 at 4:00 p.m. ET will detail the ACR-525 and PKCθ programs.
At the time of this announcement, ACRV was trading at $1.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.3M. The 52-week trading range was $1.27 to $3.56. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.